Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 148

1.

A Clinician's Guide to Next Generation Imaging in Patients With Advanced Prostate Cancer (Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence [RADAR] III).

Crawford ED, Koo PJ, Shore N, Slovin SF, Concepcion RS, Freedland SJ, Gomella LG, Karsh L, Keane TE, Maroni P, Penson D, Petrylak DP, Ross A, Mouraviev V, Reiter RE, Divgi C, Yu EY; Prostate Cancer Radiographic Assessments for Detection of Advanced Recurrence (RADAR III) Group.

J Urol. 2018 Aug 2. pii: S0022-5347(18)43643-9. doi: 10.1016/j.juro.2018.05.164. [Epub ahead of print] Review.

PMID:
30077557
2.

Radiopharmaceutical therapy in the new millenium.

Divgi CR.

J Nucl Med. 2018 Jun 29. pii: jnumed.118.214122. doi: 10.2967/jnumed.118.214122. [Epub ahead of print] No abstract available.

PMID:
29959211
3.

Imaging the multiple facets of immuno-oncology.

Divgi C.

Eur J Nucl Med Mol Imaging. 2018 Jan;45(1):121-122. doi: 10.1007/s00259-017-3869-z. No abstract available.

PMID:
29119236
4.

Prolonged red cell storage before transfusion increases extravascular hemolysis.

Rapido F, Brittenham GM, Bandyopadhyay S, La Carpia F, L'Acqua C, McMahon DJ, Rebbaa A, Wojczyk BS, Netterwald J, Wang H, Schwartz J, Eisenberger A, Soffing M, Yeh R, Divgi C, Ginzburg YZ, Shaz BH, Sheth S, Francis RO, Spitalnik SL, Hod EA.

J Clin Invest. 2017 Jan 3;127(1):375-382. doi: 10.1172/JCI90837. Epub 2016 Dec 12.

5.

An analysis of the relationship between metastases and cachexia in lung cancer patients.

Shiono M, Huang K, Downey RJ, Consul N, Villanueva N, Beck K, Fenn K, Dietz D, Yamaguchi T, Kato S, Divgi C, Kalinsky K, Wei Y, Zhang Y, Borczuk AC, Inoue A, Halmos B, Acharyya S.

Cancer Med. 2016 Sep;5(9):2641-8. doi: 10.1002/cam4.841. Epub 2016 Aug 3.

6.

Do We Need Yet Another Hybrid Imaging Device?

Divgi C.

Acad Radiol. 2016 Feb;23(2):131. doi: 10.1016/j.acra.2015.12.002. Epub 2015 Dec 21. No abstract available.

PMID:
26719162
7.

Cross-sectional and Test-Retest Characterization of PET with [(18)F]FP-(+)-DTBZ for β Cell Mass Estimates in Diabetes.

Freeby MJ, Kringas P, Goland RS, Leibel RL, Maffei A, Divgi C, Ichise M, Harris PE.

Mol Imaging Biol. 2016 Apr;18(2):292-301. doi: 10.1007/s11307-015-0888-7. Epub 2015 Sep 14.

8.

Single Institution Experience with Lymphatic Microsurgical Preventive Healing Approach (LYMPHA) for the Primary Prevention of Lymphedema.

Feldman S, Bansil H, Ascherman J, Grant R, Borden B, Henderson P, Ojo A, Taback B, Chen M, Ananthakrishnan P, Vaz A, Balci F, Divgi CR, Leung D, Rohde C.

Ann Surg Oncol. 2015 Oct;22(10):3296-301. doi: 10.1245/s10434-015-4721-y. Epub 2015 Jul 23.

PMID:
26202566
9.

PET-based compartmental modeling of (124)I-A33 antibody: quantitative characterization of patient-specific tumor targeting in colorectal cancer.

Zanzonico P, Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Smith-Jones P, Ruan S, Divgi C, Scott AM, Kemeny NE, Fong Y, Wong D, Scheinberg D, Ritter G, Jungbluth A, Old LJ, Larson SM.

Eur J Nucl Med Mol Imaging. 2015 Oct;42(11):1700-1706. doi: 10.1007/s00259-015-3061-2. Epub 2015 Jul 21.

10.

Indium 111-labeled J591 anti-PSMA antibody for vascular targeted imaging in progressive solid tumors.

Pandit-Taskar N, O'Donoghue JA, Divgi CR, Wills EA, Schwartz L, Gönen M, Smith-Jones P, Bander NH, Scher HI, Larson SM, Morris MJ.

EJNMMI Res. 2015 Apr 29;5:28. doi: 10.1186/s13550-015-0104-4. eCollection 2015.

11.

Whole-body low-dose computed tomography and advanced imaging techniques for multiple myeloma bone disease.

Pianko MJ, Terpos E, Roodman GD, Divgi CR, Zweegman S, Hillengass J, Lentzsch S.

Clin Cancer Res. 2014 Dec 1;20(23):5888-97. doi: 10.1158/1078-0432.CCR-14-1692. Epub 2014 Oct 7. Review.

12.

Imaging approaches with advanced prostate cancer: techniques and timing.

Leung D, Krishnamoorthy S, Schwartz L, Divgi C.

Can J Urol. 2014 Apr;21(2 Supp 1):42-7. Review.

13.

Antibody-based tumor vascular theranostics targeting endosialin/TEM1 in a new mouse tumor vascular model.

Li C, Chacko AM, Hu J, Hasegawa K, Swails J, Grasso L, El-Deiry WS, Nicolaides N, Muzykantov VR, Divgi CR, Coukos G.

Cancer Biol Ther. 2014 Apr;15(4):443-51. doi: 10.4161/cbt.27825. Epub 2014 Feb 19.

14.

Development of 124I immuno-PET targeting tumor vascular TEM1/endosialin.

Chacko AM, Li C, Nayak M, Mikitsh JL, Hu J, Hou C, Grasso L, Nicolaides NC, Muzykantov VR, Divgi CR, Coukos G.

J Nucl Med. 2014 Mar;55(3):500-507. doi: 10.2967/jnumed.113.121905. Epub 2014 Feb 13.

15.

Whither goest thou, radiopharmaceutical therapy?

Divgi C.

J Nucl Med. 2014 Jan;55(1):5-6. doi: 10.2967/jnumed.113.127837. Epub 2013 Dec 5. No abstract available.

16.

Phase 1 and pharmacodynamic trial of everolimus in combination with cetuximab in patients with advanced cancer.

Ciunci CA, Perini RF, Avadhani AN, Kang HC, Sun W, Redlinger M, Harlacker K, Flaherty KT, Giantonio BJ, Rosen MA, Divgi CR, Song HK, Englander S, Troxel A, Schnall M, O'Dwyer PJ.

Cancer. 2014 Jan 1;120(1):77-85. doi: 10.1002/cncr.28294. Epub 2013 Sep 24.

17.

Pilot study of PET imaging of 124I-iodoazomycin galactopyranoside (IAZGP), a putative hypoxia imaging agent, in patients with colorectal cancer and head and neck cancer.

O'Donoghue JA, Guillem JG, Schöder H, Lee NY, Divgi CR, Ruby JA, Humm JL, Lee-Kong SA, Burnazi EM, Cai S, Carlin SD, Leibold T, Zanzonico PB, Ling CC.

EJNMMI Res. 2013 Jun 3;3(1):42. doi: 10.1186/2191-219X-3-42.

18.

A review of contemporary data on surgically resected renal masses--benign or malignant?

Corcoran AT, Russo P, Lowrance WT, Asnis-Alibozek A, Libertino JA, Pryma DA, Divgi CR, Uzzo RG.

Urology. 2013 Apr;81(4):707-13. doi: 10.1016/j.urology.2013.01.009. Epub 2013 Feb 26. Review.

PMID:
23453080
19.

Positron emission tomography/computed tomography identification of clear cell renal cell carcinoma: results from the REDECT trial.

Divgi CR, Uzzo RG, Gatsonis C, Bartz R, Treutner S, Yu JQ, Chen D, Carrasquillo JA, Larson S, Bevan P, Russo P.

J Clin Oncol. 2013 Jan 10;31(2):187-94. doi: 10.1200/JCO.2011.41.2445. Epub 2012 Dec 3.

20.

American Journal of Nuclear Medicine and Molecular Imaging: Editorial Board (2012) e-Century Publishing Corporation.

Seto B, Jacobs PM, Mach RH, Bulte JW, Cai W, Alavi A, Divgi CR, Wu JC.

Am J Nucl Med Mol Imaging. 2012;2(4):508-13. Epub 2012 Oct 15. No abstract available.

21.

Radiation dosimetry and biodistribution of the hypoxia tracer (18)F-EF5 in oncologic patients.

Lin LL, Silvoniemi A, Stubbs JB, Rengan R, Suilamo S, Solin O, Divgi C, Eskola O, Sorger JM, Stabin MG, Kachur A, Hahn SM, Grönroos TJ, Forsback S, Evans SM, Koch CJ, Minn H.

Cancer Biother Radiopharm. 2012 Sep;27(7):412-9. doi: 10.1089/cbr.2011.1130. Epub 2012 Aug 16.

PMID:
22897720
22.

The SNMMI practice guideline for therapy of thyroid disease with 131I 3.0.

Silberstein EB, Alavi A, Balon HR, Clarke SE, Divgi C, Gelfand MJ, Goldsmith SJ, Jadvar H, Marcus CS, Martin WH, Parker JA, Royal HD, Sarkar SD, Stabin M, Waxman AD.

J Nucl Med. 2012 Oct;53(10):1633-51. doi: 10.2967/jnumed.112.105148. Epub 2012 Jul 11. No abstract available.

23.

Bone marrow dosimetry using 124I-PET.

Schwartz J, Humm JL, Divgi CR, Larson SM, O'Donoghue JA.

J Nucl Med. 2012 Apr;53(4):615-21. doi: 10.2967/jnumed.111.096453. Epub 2012 Mar 13.

24.

Fluorodeoxyglucose-induced allergic reaction: a case report.

Codreanu I, Dasanu CA, Weinstein GS, Divgi C.

J Oncol Pharm Pract. 2013 Mar;19(1):86-8. doi: 10.1177/1078155211436023. Epub 2012 Jan 20.

PMID:
22267446
25.

Preparation and characterization of L-[5-11C]-glutamine for metabolic imaging of tumors.

Qu W, Oya S, Lieberman BP, Ploessl K, Wang L, Wise DR, Divgi CR, Chodosh LA, Thompson CB, Kung HF.

J Nucl Med. 2012 Jan;53(1):98-105. doi: 10.2967/jnumed.111.093831. Epub 2011 Dec 15. Erratum in: J Nucl Med. 2012 Apr;53(4):646. Chodosh, Lewis P [corrected to Chodosh, Lewis A].

26.

Dosimetric considerations in radioimmunotherapy and systemic radionuclide therapies: a review.

Loke KS, Padhy AK, Ng DC, Goh AS, Divgi C.

World J Nucl Med. 2011 Jul;10(2):122-38. doi: 10.4103/1450-1147.89780.

27.

124I-huA33 antibody uptake is driven by A33 antigen concentration in tissues from colorectal cancer patients imaged by immuno-PET.

O'Donoghue JA, Smith-Jones PM, Humm JL, Ruan S, Pryma DA, Jungbluth AA, Divgi CR, Carrasquillo JA, Pandit-Taskar N, Fong Y, Strong VE, Kemeny NE, Old LJ, Larson SM.

J Nucl Med. 2011 Dec;52(12):1878-85. doi: 10.2967/jnumed.111.095596. Epub 2011 Nov 8.

28.

Targeted systemic radiotherapy of pheochromocytoma and medullary thyroid cancer.

Divgi C.

Semin Nucl Med. 2011 Sep;41(5):369-73. doi: 10.1053/j.semnuclmed.2011.05.004. Review.

PMID:
21803187
29.

Current role of metaiodobenzylguanidine in the diagnosis of pheochromocytoma and medullary thyroid cancer.

Ilias I, Divgi C, Pacak K.

Semin Nucl Med. 2011 Sep;41(5):364-8. doi: 10.1053/j.semnuclmed.2011.03.003. Review.

30.

(124)I-huA33 antibody PET of colorectal cancer.

Carrasquillo JA, Pandit-Taskar N, O'Donoghue JA, Humm JL, Zanzonico P, Smith-Jones PM, Divgi CR, Pryma DA, Ruan S, Kemeny NE, Fong Y, Wong D, Jaggi JS, Scheinberg DA, Gonen M, Panageas KS, Ritter G, Jungbluth AA, Old LJ, Larson SM.

J Nucl Med. 2011 Aug;52(8):1173-80. doi: 10.2967/jnumed.110.086165. Epub 2011 Jul 15.

31.
32.

Human Mu Opioid Receptor (OPRM1 A118G) polymorphism is associated with brain mu-opioid receptor binding potential in smokers.

Ray R, Ruparel K, Newberg A, Wileyto EP, Loughead JW, Divgi C, Blendy JA, Logan J, Zubieta JK, Lerman C.

Proc Natl Acad Sci U S A. 2011 May 31;108(22):9268-73. doi: 10.1073/pnas.1018699108. Epub 2011 May 16.

33.

Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250.

Pryma DA, O'Donoghue JA, Humm JL, Jungbluth AA, Old LJ, Larson SM, Divgi CR.

J Nucl Med. 2011 Apr;52(4):535-40. doi: 10.2967/jnumed.110.083295. Epub 2011 Mar 18.

34.

American Journal of Nuclear Medicine and Molecular Imaging: Editorial Board (2011) e-Century Publishing Corporation.

Seto B, Jacobs PM, Mach RH, Bulte JW, Cai W, Alavi A, Divgi CR, Wu JC.

Am J Nucl Med Mol Imaging. 2011;1(1):80-3. Epub 2011 Aug 3. No abstract available.

35.

Launch of the american journal of nuclear medicine and molecular imaging.

Seto B, Jacobs PM, Alavi A, Mach RH, Divgi CR, Bulte JW, Wu JC, Cai W.

Am J Nucl Med Mol Imaging. 2011;1(1):1-2. Epub 2011 Aug 3. No abstract available.

36.

Sequential cytarabine and alpha-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia.

Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, Heaney ML, Chanel S, Morgenstern A, Sgouros G, Larson SM, Scheinberg DA, Jurcic JG.

Clin Cancer Res. 2010 Nov 1;16(21):5303-11. doi: 10.1158/1078-0432.CCR-10-0382. Epub 2010 Sep 21.

37.

Biodistribution and dosimetry of (18)F-EF5 in cancer patients with preliminary comparison of (18)F-EF5 uptake versus EF5 binding in human glioblastoma.

Koch CJ, Scheuermann JS, Divgi C, Judy KD, Kachur AV, Freifelder R, Reddin JS, Karp J, Stubbs JB, Hahn SM, Driesbaugh J, Smith D, Prendergast S, Evans SM.

Eur J Nucl Med Mol Imaging. 2010 Nov;37(11):2048-59. doi: 10.1007/s00259-010-1517-y. Epub 2010 Jun 29.

38.

Intravenous bisphosphonate therapy does not acutely alter nuclear bone scan results.

Morris PG, Poznak CV, Modi S, Mak AF, Patil S, Larson S, Hudis CA, Divgi C, Grewal RK.

Clin Breast Cancer. 2010 Feb;10(1):33-9. doi: 10.3816/CBC.2010.n.004.

PMID:
20133256
39.

Molecular imaging of pulmonary cancer and inflammation.

Divgi CR.

Proc Am Thorac Soc. 2009 Aug 15;6(5):464-8. doi: 10.1513/pats.200902-005AW. Review.

40.

Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

Andersson H, Cederkrantz E, Bäck T, Divgi C, Elgqvist J, Himmelman J, Horvath G, Jacobsson L, Jensen H, Lindegren S, Palm S, Hultborn R.

J Nucl Med. 2009 Jul;50(7):1153-60. doi: 10.2967/jnumed.109.062604. Epub 2009 Jun 12.

41.

Targeted therapy of renal cell carcinoma: synergistic activity of cG250-TNF and IFNg.

Bauer S, Oosterwijk-Wakka JC, Adrian N, Oosterwijk E, Fischer E, Wüest T, Stenner F, Perani A, Cohen L, Knuth A, Divgi C, Jäger D, Scott AM, Ritter G, Old LJ, Renner C.

Int J Cancer. 2009 Jul 1;125(1):115-23. doi: 10.1002/ijc.24359.

42.

Phase I study of samarium-153 lexidronam with docetaxel in castration-resistant metastatic prostate cancer.

Morris MJ, Pandit-Taskar N, Carrasquillo J, Divgi CR, Slovin S, Kelly WK, Rathkopf D, Gignac GA, Solit D, Schwartz L, Stephenson RD, Hong C, Delacruz A, Curley T, Heller G, Jia X, O'Donoghue J, Larson S, Scher HI.

J Clin Oncol. 2009 May 20;27(15):2436-42. doi: 10.1200/JCO.2008.20.4164. Epub 2009 Apr 13. Erratum in: J Clin Oncol. 2011 Oct 10;29(29):3947-8.

43.

Dosimetry of 11C-carfentanil, a micro-opioid receptor imaging agent.

Newberg AB, Ray R, Scheuermann J, Wintering N, Saffer J, Schmitz A, Freifelder R, Karp J, Lerman C, Divgi C.

Nucl Med Commun. 2009 Apr;30(4):314-8. doi: 10.1097/MNM.0b013e328329a0ec.

PMID:
19242386
44.

CT and 111In-pentetreotide SPECT of hilar ACTH-producing neuroendocrine tumor associated with Cushing's syndrome and massive bilateral adrenal gland hyperplasia.

Chamroonrat W, Torigian DA, Gefter WB, Litzky LA, Divgi C.

J Radiol Case Rep. 2009;3(8):1-4. doi: 10.3941/jrcr.v3i8.197. Epub 2009 Aug 1.

45.

Molecular imaging of renal cell carcinoma.

Perini R, Pryma D, Divgi C.

Urol Clin North Am. 2008 Nov;35(4):605-11; vi. doi: 10.1016/j.ucl.2008.07.015. Review.

PMID:
18992614
46.

Radioiodine imaging and treatment in thyroid disorders.

Griggs WS, Divgi C.

Neuroimaging Clin N Am. 2008 Aug;18(3):505-15, viii. doi: 10.1016/j.nic.2008.03.008. Review.

PMID:
18656031
47.

Antibody mass escalation study in patients with castration-resistant prostate cancer using 111In-J591: lesion detectability and dosimetric projections for 90Y radioimmunotherapy.

Pandit-Taskar N, O'Donoghue JA, Morris MJ, Wills EA, Schwartz LH, Gonen M, Scher HI, Larson SM, Divgi CR.

J Nucl Med. 2008 Jul;49(7):1066-74. doi: 10.2967/jnumed.107.049502. Epub 2008 Jun 13.

48.

Non-invasive assessment of tumor neovasculature: techniques and clinical applications.

Perini R, Choe R, Yodh AG, Sehgal C, Divgi CR, Rosen MA.

Cancer Metastasis Rev. 2008 Dec;27(4):615-30. doi: 10.1007/s10555-008-9147-6. Review.

PMID:
18506398
49.

The use of positron-emission tomography in the diagnosis of tumour phenotype.

Divgi C.

BJU Int. 2008 Jun;101 Suppl 4:36-8. doi: 10.1111/j.1464-410X.2008.07647.x. Review. No abstract available.

50.

The promise of locoregional radiopharmaceutical therapy: will it ever be realized?

Divgi C.

J Nucl Med. 2008 Mar;49(3):340. doi: 10.2967/jnumed.107.047639. No abstract available.

Supplemental Content

Support Center